Ekso Bionics Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Include Personal Exoskeletons within a Medicare Benefit Category
27 Septiembre 2023 - 7:00AM
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an
industry leader in exoskeleton technology for medical and
industrial use, supports the Centers for Medicare & Medicaid
Services (“CMS”) proposal to include personal exoskeletons in the
Medicare benefit category for braces in the updated 2024 Home
Health Prospective Payment System Rate.
“This newly proposed rule is highly relevant for
our business and individuals with a spinal cord injury and reflects
a positive step in facilitating the potential for Medicare coverage
of personal exoskeletons, such as our Ekso Indego Personal, for
qualified patients as a lump sum reimbursement,” said Scott Davis,
Chief Executive Officer of Ekso Bionics. “We fully support the
codifying of the proposal to further enhance potential access for
Medicare beneficiaries and look forward to the CMS regulations
expected later this year, including potential reimbursement
levels.”
The proposed CMS rule would codify the
longstanding Medicare definition of brace to provide clarification
on the scope of the Medicare Part B benefit for leg, arm, back, and
neck braces, and as a result, would classify certain
exoskeleton-type devices as braces for Medicare payment purposes.
Currently, of the 294,000 individuals with spinal cord injury
(“SCI”) prevalence1 only 56% of are covered by Medicare or Medicaid
five years post injury.2 If approved, the proposed rule could
significantly expand the addressable market for Ekso Indego
Personal.
Debbie Wagoner, an individual with a SCI,
recognized the life changing benefits from using an Ekso Indego
Personal. To preserve her quality of life, Ms. Wagoner purchased
her own device through a time-intensive and costly self-fundraise,
since the Ekso Indego Personal was not covered under Medicare and
Medicaid benefits. Under the proposed CMS rule change, more
individuals with a SCI who have Medicare and Medicaid benefits,
like Ms. Wagoner, could obtain their Ekso Indego Personal device at
a considerably lower cost.
“My neurologist thinks my drastically reduced
pain and improved quality of life are largely due to the Ekso
Indego Personal,” said Ms. Wagoner. “I had peace with my SCI from
the beginning and knew there was a purpose. I want to show the
world how I reacquired independence and instill hope in other
individuals with SCI who deserve to get their freedom back
too.”
Reference1National Spinal Cord
Injury Statistical Center, 2020 SCI Data Sheet, Spinal Cord Injury
Facts and Figures at a Glance2National Spinal Cord Injury
Statistical Center SCIMS 2022 Annual Report
About Ekso Bionics® Ekso
Bionics® is a leading developer of exoskeleton solutions that
amplify human potential by supporting or enhancing strength,
endurance and mobility across medical and industrial applications.
Founded in 2005, the Company continues to build upon its
industry-leading expertise to design some of the most cutting-edge,
innovative wearable robots available on the market. Ekso Bionics is
the only known exoskeleton company to offer technologies that range
from helping those with paralysis to stand up and walk, to
enhancing human capabilities on job sites across the globe. The
Company is headquartered in the San Francisco Bay Area and is
listed on the Nasdaq Capital Market under the symbol “EKSO.” For
more information, visit: www.eksobionics.com or follow @EksoBionics
on Twitter.
Forward Looking StatementsThis
press release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements include, without limitation, statements
regarding the terms and impact of the proposed CMS rules and the
timing for the final CMS rules. Forward-looking statements can be
identified by words such as “expect,” “continue,” “anticipate,”
“estimate,” “believe,” “plan,” “projection,” “grow,” “potential,”
“future,” “can,” “develop,” “proposition,” “position,” “expand” or
words of similar meaning. Actual results and the timing of certain
events and circumstances may differ materially from those described
by the forward-looking statements as a result of risks and
uncertainties. Factors that may influence or contribute to the
inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the final CMS rules being different
that the proposed rules and the CMS rules not being finalized.
These and other factors are identified and described in more detail
in the Company's public filings with the Securities and Exchange
Commission ("SEC”). You should carefully read the Cautionary Note
Regarding Forward-Looking Statements and the factors described in
the "Risk Factors" section of the Company’s periodic reports filed
with the Securities and Exchange Commission to better understand
the risks and uncertainties inherent in the Company. The Company
does not undertake to update these forward-looking statements,
except as required by law.
Contact: David
Carey 212-867-1768 investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Ekso Bionics (NASDAQ:EKSO)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024